Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cutia Therapeutics ( (HK:2487) ).
Cutia Therapeutics has announced a change in its company secretary, authorized representative, and process agent, with Ms. Chan Sze Ting resigning and Mr. Leung Chi Kit taking over the roles effective August 28, 2025. Additionally, the company has relocated its principal place of business in Hong Kong to a new address, indicating strategic operational adjustments.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, operating within the therapeutic industry. It focuses on providing innovative healthcare solutions and services, with its shares listed on the Hong Kong Stock Exchange.
Average Trading Volume: 1,252,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.14B
See more data about 2487 stock on TipRanks’ Stock Analysis page.